South Korea Approves First Epilepsy Drug Under New Fast-Track Review Process
核心洞察
South Korea's Ministry of Food and Drug Safety (搜索) approved Xcoprijeong (搜索) (cenobamate) as the 41st domestically developed new drug, marking the first approval under new fast-track guidelines.
The epilepsy (搜索) treatment is authorized as adjunctive therapy for partial seizures (搜索) in adults and addresses high patient demand after FDA approval in 2019 with over 140,000 cumulative prescriptions.
SK Biopharmaceuticals (搜索) developed the sodium channel blocker, while Dong-A ST (搜索) holds licensing rights and plans to supply the drug to 30 countries globally.
South Korea's Ministry of Food and Drug Safety (搜索) has approved Xcoprijeong (搜索) (cenobamate) as the country's 41st domestically developed new drug, marking a significant milestone as the first treatment to receive authorization under the ministry's new fast-track review guidelines for epilepsy (搜索) medications.
The drug is authorized as adjunctive therapy for partial seizures (搜索) with or without secondary generalized seizures (搜索) in adult epilepsy (搜索) patients. The approval addresses a critical unmet need for patients who have not achieved adequate seizure control with existing anti-epileptic drugs, providing new treatment opportunities for this patient population.
Breakthrough Fast-Track Approval Process
Xcoprijeong (搜索) represents the inaugural case of applying the Ministry of Food and Drug Safety (搜索)'s "new drug product approval and review business procedure" guidelines, which were enacted this year to accelerate the approval of innovative treatments. The ministry assembled a dedicated 21-person review team comprising new drug approval experts to expedite the evaluation process.
The streamlined approach included priority screening for Good Clinical Practice (GCP) compliance and Good Manufacturing Practice (GMP) standards, along with eight customized face-to-face meetings conducted before and after the approval application submission. This comprehensive support system demonstrates the ministry's commitment to reducing regulatory timelines for critical medications.
Mechanism of Action and Clinical Impact
Xcoprijeong (搜索) functions as a sodium channel blocker that normalizes the balance between excitatory and inhibitory signals in nerve cells by blocking sodium channels (搜索) responsible for transmitting excitatory signals to the brain. This mechanism helps restore proper neuronal function in epilepsy (搜索) patients.
The drug received marketing approval from the U.S. Food and Drug Administration in 2019 and has demonstrated substantial clinical adoption, with cumulative prescription numbers exceeding 140,000 patients. Despite this international success, the treatment had not been available in South Korea, creating significant patient demand for prompt domestic introduction to address the inconvenience faced by patients who previously required overseas prescriptions.
Commercial Development and Global Distribution
SK Biopharmaceuticals (搜索) developed Xcoprijeong (搜索) through its proprietary research and development efforts. Dong-A ST (搜索) holds the licensing, sales, and production rights for the medication and received finished drug production technology transfer from SK Biopharmaceuticals in January of the previous year.
The commercial strategy extends beyond South Korea, with Dong-A ST (搜索) planning to supply Xcoprijeong (搜索) to 30 countries worldwide. The company is currently working to expedite domestic insurance drug pricing negotiations and registration processes to ensure patient access.
Regulatory Innovation Impact
The Ministry of Food and Drug Safety (搜索) emphasized its commitment to enhancing the drug approval system, stating that it will "strive to increase the predictability, transparency, and speed of the permit review so that safe and effective drugs can be provided to patients quickly."
This approval demonstrates South Korea's evolving regulatory landscape, where patient advocacy through academic societies, patient organizations, and national petitions contributed to prioritizing this treatment's review process. The success of this fast-track approach may serve as a model for future innovative drug approvals in the country.